Critical Outcome T (OTCMKTS:COTQF) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Friday.

Separately, Zacks Investment Research upgraded Critical Outcome T from a “sell” rating to a “hold” rating in a report on Wednesday, December 6th.

Critical Outcome T (OTCMKTS COTQF) opened at $0.59 on Friday. The stock has a market capitalization of $11.56, a P/E ratio of -2.27 and a beta of 229.46. Critical Outcome T has a fifty-two week low of $0.59 and a fifty-two week high of $4.80.

Critical Outcome T (OTCMKTS:COTQF) last announced its quarterly earnings results on Friday, December 29th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. equities analysts expect that Critical Outcome T will post -0.3 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Critical Outcome T (COTQF) Raised to “Sell” at ValuEngine” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at

About Critical Outcome T

Critical Outcome Technologies Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer in Canada. The company’s proprietary artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Critical Outcome T Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Critical Outcome T and related companies with's FREE daily email newsletter.